Drug development firm ImmuPharma said Monday that its key scientific collaboration partner and the inventor of ImmuPharma's lead compound, Lupuzor, has confirmed the effectiveness of a product known as Lupuzor peptide P140.
Partner CNRS released a statement saying that in a clinical trial involving 149 patients suffering with the Lupus, an autoimmune disease, the peptide was well tolerated by patients and led to a regression of the disease.
It said: "Under the CNRS patent, ImmuPharma-France, which funded the trial, has an exclusive licence to use the peptide. Now the final phase of clinical tests should soon confirm these results and contribute to the development of a drug without the side effects of existing treatments, which use cortico-steroids and immuno-suppressants."
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
The share price rose 9.73% to 62p by 13:40.
NR
-
ScottishPower launches half-price electricity at weekendsNews ScottishPower is offering 50% off electricity at weekends, which could slash hundreds off your bill. We look at who can get it and how to apply
-
Trump calls “tariff” the “most beautiful word in the dictionary”, but investors may disagreeDonald Trump has promised to slap Mexico, Canada and China with new tariffs on day one of his presidency. What does it mean for the economy and investors?
